January 2023
1. KATSUYA H, Yamaguchi K, Dung TC, Sano H, et al
   Late graft failure with donor-derived GPI-deficient cells in a mixed chimera following allogeneic bone marrow transplantation for severe aplastic anemia.
   Bone Marrow Transplant. 2023 Jan 21. doi: 10.1038/s41409-023-01923.
   

   >> Share

   
   November 2022
2. KHARYA G, Sapkota S, Teotia N, Chaudhary M, et al
   Thiotepa-based reduced toxicity conditioning in combination with post-transplant cyclophosphamide and mTOR inhibitor for heavily transfused acquired severe aplastic anemia in children and young adults: encouraging outcomes of a pilot study.
   Bone Marrow Transplant. 2022 Nov 24. doi: 10.1038/s41409-022-01876.
   

   >> Share

   
   
3. SANTARONE S, Angelini S, Natale A, Vaddinelli D, et al
   Survival and late effects of hematopoietic cell transplantation in patients with thalassemia major.
   Bone Marrow Transplant. 2022;57:1689-1697.
   

   >> Share

   
   October 2022
4. XU L, Lu Y, Chen J, Sun S, et al
   Fludarabine- and low-dose cyclophosphamide-based conditioning regimens provided favorable survival and engraftment for unmanipulated hematopoietic cell transplantation from unrelated donors and matched siblings in patients with Fanconi anemia: results
   Bone Marrow Transplant. 2022 Oct 18. pii: 10.1038/s41409-022-01838.
   

   >> Share

   
   September 2022
5. MULAS O, Caocci G, Efficace F, Piras E, et al
   Long-term health-related quality of life in patients with beta-thalassemia after unrelated hematopoietic stem cell transplantation.
   Bone Marrow Transplant. 2022 Sep 16. pii: 10.1038/s41409-022-01823.
   

   >> Share

   
   July 2022
6. PRABAHRAN A, Koldej R, Chee L, Szer J, et al
   Non-relapse cytopenias following allogeneic stem cell transplantation, a case based review.
   Bone Marrow Transplant. 2022 Jul 23. pii: 10.1038/s41409-022-01761.
   

   >> Share

   
   
7. RANGARAJAN HG, Crowell SA, Towerman AS, Shenoy SS, et al
   CD34-selected stem cell boost as therapy for late graft rejection following allogeneic transplantation for sickle cell disease.
   Bone Marrow Transplant. 2022 Jul 7. pii: 10.1038/s41409-022-01749.
   

   >> Share

   
   
8. XU LP, Xu ZL, Zhang YY, Cheng YF, et al
   Bulsufan decreases the incidence of mixed chimaerism in HLA-matched donor transplantation for severe aplastic anaemia.
   Bone Marrow Transplant. 2022;57:1204-1206.
   

   >> Share

   
   June 2022
9. TANG L, Wu Y, Lei R, Liu J, et al
   Adding 5-day decitabine to the conditioning regimen for haploidentical bone marrow transplantation in aplastic anaemia patients results in satisfactory clinical outcomes.
   Bone Marrow Transplant. 2022 Jun 22. pii: 10.1038/s41409-022-01729.
   

   >> Share

   
   April 2022
10. LIANG H, Pan L, Xie Y, Fan J, et al
    Health-related quality of life in pediatric patients with beta-thalassemia major after hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2022 Apr 29. pii: 10.1038/s41409-022-01663.
    

    >> Share

    
    February 2022
11. YESILIPEK MA, Uygun V, Kupesiz A, Karasu G, et al
    Thalassemia-free and graft-versus-host-free survival: outcomes of hematopoietic stem cell transplantation for thalassemia major, Turkish experience.
    Bone Marrow Transplant. 2022 Feb 24. pii: 10.1038/s41409-022-01613.
    

    >> Share

    
    
12. ARSLAN S, Ali H, Mei M, Marcucci G, et al
    Successful treatment of refractory pure red cell aplasia in major ABO-mismatched allogeneic hematopoietic stem cell transplant with single agent Ibrutinib.
    Bone Marrow Transplant. 2022 Feb 22. pii: 10.1038/s41409-022-01590.
    

    >> Share

    
    
13. PARSONS SK, Rodday AM, Weidner RA, Morris E, et al
    Significant improvement of child physical and emotional functioning after familial haploidentical stem cell transplant.
    Bone Marrow Transplant. 2022 Feb 2. pii: 10.1038/s41409-022-01584.
    

    >> Share

    
    
14. DAMLAJ M, Alahmari B, Alaskar A, Alhejazi A, et al
    Feasibility of early sirolimus cessation post non-myeloablative transplantation in adult patients with severe sickle cell disease.
    Bone Marrow Transplant. 2022;57:319-322.
    

    >> Share

    
    December 2021
15. IFTIKHAR R, Ahmad P, de Latour R, Dufour C, et al
    Correction to: Special issues related to the diagnosis and management of acquired aplastic anemia in countries with restricted resources, a report on behalf of the Eastern Mediterranean Blood and Marrow Transplantation (EMBMT) Group and Severe Aplasti
    Bone Marrow Transplant. 2021 Dec 20. pii: 10.1038/s41409-021-01534.
    

    >> Share

    
    
16. OIKONOMOPOULOU C, Goussetis E
    HSCT remains the only cure for patients with transfusion-dependent thalassemia until gene therapy strategies are proven to be safe.
    Bone Marrow Transplant. 2021;56:2882-2888.
    

    >> Share

    
    November 2021
17. HASHEM H, Rihani R, Shanap MA, Khattab E, et al
    Novel conditioning regimen for upfront haploidentical hematopoietic cell transplantation in children with severe aplastic anemia and donor-specific anti-HLA antibodies.
    Bone Marrow Transplant. 2021 Nov 27. pii: 10.1038/s41409-021-01536.
    

    >> Share

    
    
18. ROVO A, Tichelli A
    Cancers after hematopoietic cell transplantation for aplastic anemia-the importance of persistence.
    Bone Marrow Transplant. 2021 Nov 9. pii: 10.1038/s41409-021-01514.
    

    >> Share

    
    
19. ALZAHRANI M, Damlaj M, Essa M, Alahmari B, et al
    HLA-identical related hematopoietic stem cell transplantation in severe sickle cell disease: age is not a barrier to successful outcome.
    Bone Marrow Transplant. 2021 Nov 6. pii: 10.1038/s41409-021-01513.
    

    >> Share

    
    
20. JOHN TD, Friend B, Yassine K, Sasa G, et al
    Matched related hematopoietic cell transplant for sickle cell disease with alemtuzumab: the Texas Children's Hospital experience.
    Bone Marrow Transplant. 2021;56:2797-2803.
    

    >> Share

    
    October 2021
21. MARTINO R, Garcia-Cadenas I, Esquirol A
    Daratumumab may be the most effective treatment for post-engraftment pure red cell aplasia due to persistent anti-donor isohemagglutinins after major ABO-mismatched allogeneic transplantation.
    Bone Marrow Transplant. 2021 Oct 28. pii: 10.1038/s41409-021-01507.
    

    >> Share

    
    
22. VO P, Onstad L, Flowers ME, Storb R, et al
    Cancers after HLA-matched related bone marrow transplantation for aplastic anemia.
    Bone Marrow Transplant. 2021 Oct 16. pii: 10.1038/s41409-021-01498.
    

    >> Share

    
    
23. DEBUREAUX PE, Kulasekararaj AG, Cacace F, Silva BGP, et al
    Categorizing hematological response to eculizumab in paroxysmal nocturnal hemoglobinuria: a multicenter real-life study.
    Bone Marrow Transplant. 2021;56:2600-2602.
    

    >> Share

    
    September 2021
24. ABUELGASIM KA, Damlaj M, Bosaeed M, Altamimi S, et al
    Infectious complications in adult sickle cell anemia patients undergoing hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2021 Sep 10. pii: 10.1038/s41409-021-01457.
    

    >> Share

    
    August 2021
25. DIAZ-DE-HEREDIA C, Bresters D, Faulkner L, Yesilipek A, et al
    Recommendations on hematopoietic stem cell transplantation for patients with Diamond-Blackfan anemia. On behalf of the Pediatric Diseases and Severe Aplastic Anemia Working Parties of the EBMT.
    Bone Marrow Transplant. 2021 Aug 31. pii: 10.1038/s41409-021-01449.
    

    >> Share

    
    
26. AKDOGAN N, Ersoy-Evans S, Visal Okur F, Kuskonmaz B, et al
    Long-term skin findings in patients with Fanconi anemia after allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2021 Aug 27. pii: 10.1038/s41409-021-01441.
    

    >> Share

    
    
27. SINGH AK, Schetzen E, Yadav SK, Lustig EB, et al
    Correction of murine sickle cell disease by allogeneic haematopoietic cell transplantation with anti-3rd party veto cells.
    Bone Marrow Transplant. 2021;56:1818-1827.
    

    >> Share

    
    July 2021
28. BLENNERHASSETT R, Moses JH, Coulits N, Horne A, et al
    Recurrent secondary graft failure likely due to a DRB4 donor-specific antibody in a patient with aplastic anemia and DRB4 null allele.
    Bone Marrow Transplant. 2021 Jul 7. pii: 10.1038/s41409-021-01402.
    

    >> Share

    
    
29. SOCIE G, Peffault de Latour R
    Secondary malignancies after transplantation for aplastic anemia.
    Bone Marrow Transplant. 2021 Jul 7. pii: 10.1038/s41409-021-01400.
    

    >> Share

    
    
30. COSTA TCM, Chiari-Correia R, Salmon CEG, Darrigo-Junior LG, et al
    Hematopoietic stem cell transplantation reverses white matter injury measured by diffusion-tensor imaging (DTI) in sickle cell disease patients.
    Bone Marrow Transplant. 2021 Jul 7. pii: 10.1038/s41409-021-01365.
    

    >> Share

    
    
31. LIU L, Miao M, Chen X, Zhang Y, et al
    Outcomes of severe aplastic anemia patients with infection proceeding with allogeneic hematopoietic stem cell transplantation, versus patients without infection.
    Bone Marrow Transplant. 2021 Jul 3. pii: 10.1038/s41409-021-01398.
    

    >> Share

    
    June 2021
32. IFTIKHAR R, Chaudhry QN, Mahmood SK, Ghafoor T, et al
    A novel TBI free conditioning protocol for haploidentical transplant in acquired aplastic anemia: (FluCAB-Prime).
    Bone Marrow Transplant. 2021 Jun 25. pii: 10.1038/s41409-021-01385.
    

    >> Share

    
    May 2021
33. IFTIKHAR R, Ahmad P, de Latour R, Dufour C, et al
    Special issues related to the diagnosis and management of acquired aplastic anemia in countries with restricted resources, a report on behalf of the Eastern Mediterranean blood and marrow transplantation (EMBMT) group and severe aplastic anemia workin
    Bone Marrow Transplant. 2021 May 19. pii: 10.1038/s41409-021-01332.
    

    >> Share

    
    
34. FRIEDMAN D, Dozor AJ, Milner J, D'Souza M, et al
    Stable to improved cardiac and pulmonary function in children with high-risk sickle cell disease following haploidentical stem cell transplantation.
    Bone Marrow Transplant. 2021 May 6. pii: 10.1038/s41409-021-01298.
    

    >> Share

    
    February 2021
35. MISKIEWICZ-BUJNA J, Miskiewicz-Migon I, Panasiuk A, Kubica-Cielinska A, et al
    Severe and fatal toxicity after hematopoietic stem cell transplantation in GNE defect-associated thrombocytopenia.
    Bone Marrow Transplant. 2021 Feb 26. pii: 10.1038/s41409-021-01235.
    

    >> Share

    
    
36. LAI X, Liu L, Zhang Z, Shi L, et al
    Hepatic veno-occlusive disease/sinusoidal obstruction syndrome after hematopoietic stem cell transplantation for thalassemia major: incidence, management, and outcome.
    Bone Marrow Transplant. 2021 Feb 19. pii: 10.1038/s41409-021-01233.
    

    >> Share

    
    
37. KHARYA G, Bakane A, Agarwal S, Rauthan A, et al
    Pre-transplant myeloid and immune suppression, upfront plerixafor mobilization and post-transplant cyclophosphamide: novel strategy for haploidentical transplant in sickle cell disease.
    Bone Marrow Transplant. 2021;56:492-504.
    

    >> Share

    
    December 2020
38. XU ZL, Huang XJ
    Haploidentical stem cell transplantation for aplastic anemia: the current advances and future challenges.
    Bone Marrow Transplant. 2020 Dec 15. pii: 10.1038/s41409-020-01169.
    

    >> Share

    
    
39. MURILLO-SANJUAN L, Gonzalez-Vicent M, Argiles Aparicio B, Badell Serra I, et al
    Survival and toxicity outcomes of hematopoietic stem cell transplantation for pediatric patients with Fanconi anemia: a unified multicentric national study from the Spanish Working Group for Bone Marrow Transplantation in Children.
    Bone Marrow Transplant. 2020 Dec 10. pii: 10.1038/s41409-020-01172.
    

    >> Share

    
    November 2020
40. MARCO-AYALA J, Gomez-Segui I, Sanz G, Solves P, et al
    Pure red cell aplasia after major or bidirectional ABO incompatible hematopoietic stem cell transplantation: to treat or not to treat, that is the question.
    Bone Marrow Transplant. 2020 Nov 14. pii: 10.1038/s41409-020-01124.
    

    >> Share

    
    October 2020
41. KOYAMAISHI S, Kamio T, Kobayashi A, Sato T, et al
    Correction: Reduced-intensity conditioning is effective for hematopoietic stem cell transplantation in young pediatric patients with Diamond-Blackfan anemia.
    Bone Marrow Transplant. 2020 Oct 14. pii: 10.1038/s41409-020-01076.
    

    >> Share

    
    May 2020
42. YOSHIDA N, Takahashi Y, Yabe H, Kobayashi R, et al
    Conditioning regimen for allogeneic bone marrow transplantation in children with acquired bone marrow failure: fludarabine/melphalan vs. fludarabine/cyclophosphamide.
    Bone Marrow Transplant. 2020 May 23. pii: 10.1038/s41409-020-0948.
    

    >> Share

    
    March 2020
43. GLUCKMAN E, Fuente J, Cappelli B, Scigliuolo GM, et al
    The role of HLA matching in unrelated donor hematopoietic stem cell transplantation for sickle cell disease in Europe.
    Bone Marrow Transplant. 2020 Mar 10. pii: 10.1038/s41409-020-0847.
    

    >> Share

    
    January 2020
44. LIU L, Zhang Y, Liu S, Zhou H, et al
    Outcomes of conditioning with rabbit antithymocyte globulin and rituximab in haploidentical haematopoietic stem cell transplantation in patients with severe aplastic anaemia.
    Bone Marrow Transplant. 2020 Jan 20. pii: 10.1038/s41409-020-0788.
    

    >> Share

    
    November 2019
45. LIU L, Zhang Y, Liu S, Zhou H, et al
    Outcomes of haploidentical haematopoietic stem cell transplantation for paroxysmal nocturnal haemoglobinuria.
    Bone Marrow Transplant. 2019 Nov 19. pii: 10.1038/s41409-019-0751.
    

    >> Share

    
    September 2019
46. MARWAH P, Soni R, Ramprakash S, Raghuram CP, et al
    The impact of Host vs. Graft mismatches on rejection of haploidentical bone marrow transplants in thalassemia patients using posttransplant cyclophosphamide.
    Bone Marrow Transplant. 2019 Sep 30. pii: 10.1038/s41409-019-0692.
    

    >> Share

    
    
47. MILLER PDE, Snowden JA, De Latour RP, Iacobelli S, et al
    Autoimmune cytopenias (AIC) following allogeneic haematopoietic stem cell transplant for acquired aplastic anaemia: a joint study of the Autoimmune Diseases and Severe Aplastic Anaemia Working Parties (ADWP/SAAWP) of the European Society for Blood and
    Bone Marrow Transplant. 2019 Sep 25. pii: 10.1038/s41409-019-0680.
    

    >> Share

    
    
48. RAUTENBERG C, Kaivers J, Germing U, Haas R, et al
    Daratumumab for treatment of pure red cell aplasia after allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2019 Sep 3. pii: 10.1038/s41409-019-0664.
    

    >> Share

    
    May 2019
49. KATOH D, Ochi Y, Hiramoto N, Morita M, et al
    Parvovirus B19 infection in adult patients after allogeneic stem cell transplantation: our experience of five cases and literature review.
    Bone Marrow Transplant. 2019 May 14. pii: 10.1038/s41409-019-0533.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share